He is the Director of Innovation at Boston Keratoprosthesis and investigates new ideas and strategies to improve corneal prosthesis. His main research involves the mitigation of retina damage after ocular injuries, and in particular the study of the role of microglial cells in neurodegeneration and neuroglial remodeling. In this context, he develops targeted antibody therapies for retinal neuroprotection. Dr. Paschalis' work extends into clinical research, in which he studies various inflammatory markers for the early detection of glaucoma in patients who received Boston keratoprosthesis surgery.